It is suggested that corilagin should be prioritized in further studies on new therapeutics which target the treatment of T2DM and/or asthma because of its dual inhibitory activity against AGLUC and LOX, as well as its several beneficial pharmacological activities and low reported toxicity. This evidence concerns the gene LOX and asthma.